We report a phase II study to evaluate the survival rate, response rate and @entity137 of concurrent chemoradiation therapy (CCRT) followed by consolidation chemotherapy (CT) with oral @entity2879 and @entity900 for @entity1 with locally advanced inoperable @entity1149 ( @entity1149 ). Fifty-four @entity1 with locally advanced inoperable @entity1149 who had received no prior therapy were enrolled into this trial between May 1995 and December 2000. Treatment consisted of two cycles of concurrent CT and four cycles of consolidation CT with oral @entity2879 (50 mg/m2) on days 1-14 during the CCRT courses and on days 1-21 during the consolidation CT courses, plus @entity900 (75 mg/m2 i.v.) on day 1 of a 28-day cycle. Conventional radiotherapy (1.8 Gy/fraction, 63 Gy over 7 weeks) was delivered from day 1 of the CT. Fifty-two @entity1 were evaluable for response. Twelve @entity1 (22%) achieved complete responses, and 32 @entity1 (60%) achieved partial responses, for an overall response rate of 82% with a median duration of response of 9.1 months. Forty-three per cent developed grade 4 haematological @entity137 , 11% grade 3 or 4 @entity354 and 7% grade 3 or 4 lung @entity137 . There were two treatment-related @entity204 , one from radiation @entity55 and the other from sepsis. After a median follow-up duration of 50 months (range 20-85), the median overall survival time was 15.3 months (95% CI, 9.7-20.8), and the 1-, 2-, 3-, and 5 year overall survival rates were 62, 40, 30 and 16%, respectively. The duration of median progression-free survival was 12.3 months (95% CI, 7.4-17.3), and the 1-, 2-, 3-, and 5-year progression-free survival rates were 47, 40, 29 and 23%, respectively. Thus, concurrent conventional chest radiotherapy with oral @entity2879 plus @entity900 followed by consolidation CT led to an encouraging survival rate and prolongation of the time to progression, with moderate @entity137 in @entity1 with locally advanced inoperable @entity1149 .

A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral XXXX and @entity900 for locally advanced inoperable @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity354 :: ('MESH:D005764', 'Disease') :: ['oesophagitis'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity2879 :: (MESH:D005047,Chemical) :: ['etoposide']
